Occurrence Rate of Non-Small Cell Lung, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey & Diagnosis and Treatment Characteristics Turkish "Non-Small Cell Lung-Colon-Gastric-Breast (CGB) Cancer and Malignant Melanoma" Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32,277
- 主要终点
- Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
研究概览
简要总结
This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma
- •Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer
排除标准
- •Participants not living in the city or representative region of the study center
结局指标
主要结局
Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
时间窗: 36 months
Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region
时间窗: 36 months
Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
时间窗: 36 months
Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
时间窗: 36 months
Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
时间窗: 36 months
次要结局
- Percentage of Participants Categorized by Surgery Type(36 months)
- Percentage of Participants Categorized by Diagnostic Methods(36 months)
- Overall Survival (OS)(36 months)
- Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)(36 months)
- Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments)(36 months)
- Percentage of Participants With Metastasis Categorized by Treatment Regimens Used (ie, First-line, Second-line, Third-line, or Forth-line Chemotherapy)(36 months)
- Percentage of Participants With History of Another Primary Cancer(36 months)
- Percentage of Participants With Metastasis(36 months)
- Percentage of Participants Categorized by Tumor Size(36 months)
- Percentage of Participants Categorized by Histopathology Diagnosis(36 months)
- Percentage of Participants Categorized by the Staging System(36 months)
- Percentage of Participants With Family History of Cancer and Other Conditions(36 months)
- Percentage of Participants Categorized by Tumor Localization(36 months)